| For: | Zhang Z, Zheng CQ. Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World J Clin Cases 2022; 10(29): 10550-10558 [PMID: 36312501 DOI: 10.12998/wjcc.v10.i29.10550] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i29/10550.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Yafang Li, Minli Hu, Yuan Chen, Xiao-Yun Yang, Qunying Wang, Jin Ding, Yibing Hu. Vedolizumab: Beyond Inflammatory Bowel Disease. Medical Principles and Practice 2025; 34(5) doi: 10.1159/000547015
|
| 3 |
Muhammad Wasim, Guoda Ma, Yajun Wang. Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1914702
|
| 4 |
Lei Xiong, Jianshang Huang, Yunsheng Dong, Wei Han, Wei-Ting Kuo, Wentao Xu, Yiran Han, Chenchen An, Rumeng Zhu, Nina Zhu, Hanqi Xia, Abduxukur Rahman, Sainan Tang, Chonggui Jiang, Junhao Zhao, Wangxiang Pei, Juan Wang, Xianda Wang, Jiayi Song, Zihan Wang, Shanshan Wu, Hui Zhang, Honghai Xu, Baoming Wu, Qiansheng Huang, Bin Bao, Qiao Mei, Huaqing Zhu, Lanlan Hou, Suthat Liangpunsakul, Feng Cao, Honglei Weng, Bei Tan, Jerrold R Turner, Hua Wang, Li Zuo. Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity. Gut 2026; 75(6) doi: 10.1136/gutjnl-2025-337780
|
| 5 |
Qian Hao, Wenwen Zhu, Qingqing Guo, Xiuxiu Lu, Shijun Zhang, Jianjun Yang, Zhonghua Song. Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1590714
|